Two more pharmaceutical companies are having difficulty supplying Adderall to US patients with attention-deficit/hyperactivity disorder as shortages plague the market. Lannett Co. and Par Pharmaceuticals, part of Endo International Plc, are the latest companies with limited supply of some doses of generic extended-release Adderall, according to a website updated Monday by the University of Utah’s drug-information service, which tracks drug shortages.